Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709)

Cytotherapy

Volumn 11, Issue 5, 2009, Pages 631-641

  Køllgaard, Tania ^a   Duval, Lone ^b   Schmidt, Henrik ^b   Kaltoft, Keld ^c   Seremet, Tina ^a   Andersen, Mads Hald ^a   Maase, Hans Von Der ^d   Straten, Per Thor ^a   Hadrup, Sine R ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Adoptive transfer; MART 1 antigen; Melanoma; T cells

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; MELAN A; T LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; C CURE 709 CELL LINE; CANCER CELL CULTURE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXICITY; DENATURING GRADIENT GEL ELECTROPHORESIS; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE MAPPING; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; MELANOMA; METASTASIS; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; ANTIGENS, NEOPLASM; BIOPSY; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CLONE CELLS; DRUG ADMINISTRATION ROUTES; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS; LONGITUDINAL STUDIES; MART-1 ANTIGEN; MIDDLE AGED; MONITORING, IMMUNOLOGIC; NEOPLASM METASTASIS; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; STAINING AND LABELING; TRANSDUCTION, GENETIC;

EID: 70849126630     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240902923146     Document Type: Article

References (32)

1. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357
2. Hakansson A, G ustafsson B, K rysander L, Hjelmqvist B, Rettrup B, Hakansson L. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infi ltrating lymphocytes. Br J Cancer 2001; 85: 1871-1877
3. Sensi M, P armiani G. A nalysis of TCR usage in human tumors: A new tool for assessing tumor-specifi c immune responses. Immunol Today 1995; 16: 588-595
4. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675
5. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99: 16168-16173
6. Kershaw MH, W estwood JA, H wu P. D ual-specifi c T cells combine proliferation and antitumor activity. Nat Biotechnol 2002; 20: 1221-1227
7. Riviere I, S adelain M, B rentjens RJ. N ovel strategies for cancer therapy: The potential of genetically modifi ed T lymphocytes. Curr Hematol Rep 2004; 3: 290-297
8. Clay TM, C uster MC, S achs J, H wu P, R osenberg SA, Nishimura MI. Effi cient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163: 507-513
9. Morgan RA, D udley ME, Wunderlich JR, H ughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129
10. Duval L, S chmidt H, K altoft K, F ode K, J ensen JJ, Sorensen SM, et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: A phase I trial in metastatic melanoma. Clin Cancer Res 2006; 12: 1229-1236
11. Sallusto F, L enig D, Forster R, L ipp M, L anzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712
12. McCutheon M, W ehner N, W ensky A, K ushner M, Doan S, Hsiao L, et al. A Sensitive ELISPOT to detect low-frequency human T lymphocytes. J Immunol. Methods 1997; 210: 149-66.
13. thor Straten P, B ecker JC, Z euthen J, G uldberg P. T-cell receptor clonotype mapping using denaturing gradient gel electrophoresis (DGGE): Analyses of clonal T-cell responses in melanoma In: Nicholoff B, ed. Melanoma Methods and Protocols. Humana Press Inc., 2001; 339-351.
14. Arden B, C lark SP, K abelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995; 42: 455-500 .
15. thor Straten P, B arfoed A, S eremet T, S aeterdal I, Z euthen J, Guldberg P. Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques 1998; 25: 244-250
16. Hadrup SR, S trindhall J, K ollgaard T, S eremet T, J ohansson B, Pawelec G, et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specifi c T cells in the very elderly. J Immunol 2006; 176: 2645-53 .
17. thor Straten P, D ahl C, S chrama D, P edersen LO, Andersen MH, Seremet T, et al. Identifi cation of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. Cancer Immunol Immunother 2006; 55: 495-502.
18. Kawakami Y, E liyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infi ltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3515-3519
19. Wang RF, Appella E, Kawakami Y, Kang X, R osenberg SA. Identifi cation of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184: 2207-2216
20. Andersen MH, B ecker JC, t hor Straten P. R egulators of apoptosis: Suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005; 4: 399-409.
21. Pittet MJ, V almori D, Dunbar PR, S peiser DE, Lienard D, Lejeune F, et al. High frequencies of naive Melan-A/MART-1-specifi c CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190: 705-715
22. Valmori D, Dutoit V, S chnuriger V, Q uiquerez AL, P ittet MJ, Guillaume P, et al. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002; 168: 4231-4240
23. + T cells in melanoma patients. J Immunol 2000; 165: 533-538 .
24. Moss PA, Moots RJ, Rosenberg WM, R owland-Jones SJ, Bodmer HC, McMichael AJ, et al. Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and infl uenza A matrix peptide. Proc Natl Acad Sci USA 1991; 88: 8987-8990
25. Dietrich PY, W alker PR, Q uiquerez AL, P errin G, D utoit V, Lienard D, et al. Melanoma patients respond to a cytotoxic T lymphocyte-defi ned self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res 2001; 61: 2047-2054
26. Speiser DE, B aumgaertner P, B arbey C, R ubio-Godoy V, Moulin A, Corthesy P, et al. A novel approach to characterize clonality and differentiation of human melanoma-specifi c T cell responses: Spontaneous priming and effi cient boosting by vaccination. J Immunol 2006; 177: 1338-1348
27. Mandruzzato S, Rossi E, Bernardi F, Tosello V, Macino B, Basso G, et al. Large and dissimilar repertoire of Melan-A/ MART-1-specifi c CTL in metastatic lesions and blood of a melanoma patient. J Immunol 2002; 169: 4017-4024
28. Trautmann L, L abarriere N, J otereau F, Karanikas V, Gervois N, Connerotte T, et al. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affi nity ranges for their specifi c antigens. Eur J Immunol 2002; 32: 3181-3190
29. Schrama D, A ndersen MH, T erheyden P, S chroder L, Pedersen LO, thor Straten P, et al. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. Cancer Res 2001; 61: 493-496
30. Andersen MH, G ehl J, R eker S, Pedersen LO, B ecker JC, Geertsen P, et al. Dynamic changes of specifi c T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003; 13: 449-459
31. De Vries IJ, B ernsen MR, v an Geloof WL, S charenborg NM, Lesterhuis WJ, Rombout PD, et al. In situ detection of antigen-specifi c T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunol Immunother 2007; 56: 1667-1676
32. Chothia C, B oswell DR, Lesk AM. T he outline structure of the T-cell alpha beta receptor. EMBO J 1988; 7: 3745-3755